Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,166 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Platelet Clear all
Completed No phase listed Observational

Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy

NCT00625248
View directory record Official record
Conditions
Bleeding
Interventions
Antithrombotics
Drug
Lead sponsor
Pain Management Center of Paducah
Other
Eligibility
18 Years and older
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

NCT04052698
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
Wilate
Drug
Lead sponsor
Octapharma
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 7, 2026, 2:57 PM EDT
Terminated Phase 1 Interventional

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

NCT01286038
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS), Thrombocytopenia
Interventions
Eltrombopag
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Early Phase 1 Interventional

The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy

NCT00727948
View directory record Official record
Conditions
Breast Cancer, Angiogenesis
Interventions
Aspirin
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 7, 2026, 2:57 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

NCT03289910
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Polycythemia Vera, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Carboplatin, Topotecan, Topotecan Hydrochloride, Veliparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 7, 2026, 2:57 PM EDT
Recruiting No phase listed Observational

ATHNdataset Registry

NCT06820515
View directory record Official record
Conditions
Hemophilia, Thrombosis, Hemophilia A, Hemophilia B, Sickle Cell Disease, Glanzmann Thrombasthenia, Bleeding Disorder, Blood Disorder, Von Willebrand Diseases
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
200,000 participants
Timeline
2024 – 2055
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 7, 2026, 2:57 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Platelet Bioenergetics in TBI

NCT04271059
View directory record Official record
Conditions
Brain Injuries, Traumatic
Interventions
Not listed
Lead sponsor
Kevin Hatton
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia

NCT04109820
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
MitoQ
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
5
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

Reduced Carbohydrate Versus Fat in Obese Subjects

NCT00846040
View directory record Official record
Conditions
Obesity
Interventions
Reduced fat diet, Reduced carbohydrate diet, Drug: f-18 fallypride, fMRI, PET
Other · Drug · Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery

NCT02283268
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand Factor (rVWF)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Aurora, Colorado • Miami, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Phase 1 Interventional

Safety of Romiplostim (Nplate®) Following UCBT

NCT02046291
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Romiplostim
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Not applicable Interventional Results available

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

NCT00360685
View directory record Official record
Conditions
Mucositis, Graft-versus-host Disease
Interventions
Tac+MTX, TAC + MMF
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Not listed
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Phase 3 Interventional

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

NCT02932618
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Vonicog alfa, Antihemophilic Factor (Recombinant)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
16
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 7, 2026, 2:57 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Early Regenerative Intervention for Post-Traumatic Osteoarthritis

NCT04222140
View directory record Official record
Conditions
Post-Traumatic Osteoarthritis of Knee
Interventions
ERIPTO Protocol, BMAC Only
Combination Product · Biological
Lead sponsor
Affinity Health Research Institute
Other
Eligibility
25 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Aurora, Illinois • Oak Brook, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced Sep 7, 2026, 2:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Assess Platelet Dysfunction With Verify Now Assay

NCT01167218
View directory record Official record
Conditions
Platelet Aggregation Defects
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 2

NCT02447783
View directory record Official record
Conditions
Healthy
Interventions
Control Capsules, Mars Cocoa Extract Capsules
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
30 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 7, 2026, 2:57 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

NCT04081220
View directory record Official record
Conditions
Thrombocythemia, Essential
Interventions
IMG-7289
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 7, 2026, 2:57 PM EDT
Recruiting Phase 2 Interventional

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

NCT06063486
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelofibrosis, Polycythemia Vera
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement, Piperine Extract (Standardized), Placebo Administration, Questionnaire Administration
Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 7, 2026, 2:57 PM EDT
Terminated No phase listed Observational

aHUS Observational Long Term Follow-Up

NCT01522170
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
16
States / cities
Atlanta, Georgia • Dunwoody, Georgia • Fort Wayne, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

NCT00391872
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
18,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
139
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Phase 4 Interventional Results available

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

NCT01848899
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Iodixanol, Ioxaglate, Bivalirudin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

NCT00054236
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, methylprednisolone
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 7, 2026, 2:57 PM EDT
Terminated No phase listed Observational

US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)

NCT04125290
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Pueblo, Colorado • Bridgeton, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 7, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans

NCT01051700
View directory record Official record
Conditions
Macular Degeneration
Interventions
GW786034, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Minneapolis, Minnesota • Austin, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 7, 2026, 2:57 PM EDT